These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16822576)

  • 1. Antibodies for angiogenesis inhibition, vascular targeting and endothelial cell transcytosis.
    Trachsel E; Neri D
    Adv Drug Deliv Rev; 2006 Aug; 58(5-6):735-54. PubMed ID: 16822576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis: an update and potential drug approaches (review).
    Abdelrahim M; Konduri S; Basha R; Philip PA; Baker CH
    Int J Oncol; 2010 Jan; 36(1):5-18. PubMed ID: 19956828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a monoclonal antibody specific for activated endothelial cells to quantitate angiogenesis in vivo in zebrafish after drug treatment.
    Seng WL; Eng K; Lee J; McGrath P
    Angiogenesis; 2004; 7(3):243-53. PubMed ID: 15609079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Based targeting of angiogenesis.
    Halin C; Neri D
    Crit Rev Ther Drug Carrier Syst; 2001; 18(3):299-339. PubMed ID: 11442202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [VEGF, anti-vEGF and diseases].
    Corvol P
    Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Targeting angiogenesis in oncology].
    Fayette J; Soria JC; Armand JP
    Pathol Biol (Paris); 2006 May; 54(4):199-205. PubMed ID: 16753494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taking down tumors: vascular disrupting agents entering clinical trials.
    O'Hanlon LH
    J Natl Cancer Inst; 2005 Sep; 97(17):1244-5. PubMed ID: 16145041
    [No Abstract]   [Full Text] [Related]  

  • 8. Basic and therapeutic aspects of angiogenesis.
    Potente M; Gerhardt H; Carmeliet P
    Cell; 2011 Sep; 146(6):873-87. PubMed ID: 21925313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.
    Abu Lila AS; Ishida T; Kiwada H
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
    Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
    Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
    Shibuya M
    FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.
    Pernasetti F; Nickel J; Clark D; Baeuerle PA; Van Epps D; Freimark B
    Int J Oncol; 2006 Dec; 29(6):1371-9. PubMed ID: 17088974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenesis: an organizing principle for drug discovery?
    Folkman J
    Nat Rev Drug Discov; 2007 Apr; 6(4):273-86. PubMed ID: 17396134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of angiogenesis at endothelial cell level.
    Jekunen A; Kairemo K
    Microsc Res Tech; 2003 Jan; 60(1):85-97. PubMed ID: 12500265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotherapeutics from natural products: from bench to clinics?
    Bernas G
    Clin Hemorheol Microcirc; 2003; 29(3-4):199-203. PubMed ID: 14724342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
    J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.
    Mousa SA; Bergh JJ; Dier E; Rebbaa A; O'Connor LJ; Yalcin M; Aljada A; Dyskin E; Davis FB; Lin HY; Davis PJ
    Angiogenesis; 2008; 11(2):183-90. PubMed ID: 18080776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour vascular targeting.
    Neri D; Bicknell R
    Nat Rev Cancer; 2005 Jun; 5(6):436-46. PubMed ID: 15928674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role of vascular targeted therapy to combat against tumor.
    Chen B; Jin H; Wu K
    Expert Opin Drug Deliv; 2009 Jul; 6(7):719-26. PubMed ID: 19538038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
    Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
    Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.